Abstract
Infliximab is a chimeric, monoclonal, anti-tumor necrosis factor (anti-TNF) antibody that is effective in the treatment of both adult and pediatric Crohn's disease (CD) [10]. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.
| Original language | English |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | International Journal of Clinical Reviews |
| State | Published - 2012 |
Bibliographical note
Copyright - Copyright Remedica Medical Education and Publishing Apr 2012Last updated - 2020-11-24
Keywords
- Medical Sciences
- Inflammatory bowel disease
- Drug therapy
- Studies
- Biological products
- TNF inhibitors
- Lymphoma
